2019
The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)
Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Bacterial AgentsAntimicrobial StewardshipFebrile NeutropeniaFemaleHematopoietic Stem Cell TransplantationHumansMaleMedication Therapy ManagementMethicillin-Resistant Staphylococcus aureusMiddle AgedNoseRetrospective StudiesStaphylococcal InfectionsTime FactorsVancomycinYoung AdultConceptsHematopoietic stem cell transplant recipientsPost-intervention cohortFebrile neutropeniaVancomycin useVancomycin discontinuationStewardship teamRetrospective analysisMultimodal approachStem cell transplant recipientsResistant Gram-positive organismsResistant Gram-positive infectionsAntibiotic stewardship teamDiscontinuation of vancomycinEvidence of pneumoniaPost-implementation cohortPrevious MRSA infectionCell transplant recipientsGram-positive infectionsNasal swab collectionEmpiric vancomycinFN patientsVancomycin ordersVancomycin usageHSCT recipientsTransplant recipients
2006
Outpatient high‐dose melphalan in multiple myeloma patients
Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients. Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmbulatory CareAnti-Bacterial AgentsAntibiotic ProphylaxisAntineoplastic Agents, AlkylatingBacteremiaCeftriaxoneDose-Response Relationship, DrugFeverHospitalizationHumansIncidenceLength of StayMelphalanMiddle AgedMultiple MyelomaNeutropeniaRetrospective StudiesStaphylococcal InfectionsStem Cell TransplantationConceptsHigh-dose melphalanOnset of neutropeniaPrimary care providersOutpatient settingMean durationPeripheral blood progenitor cell infusionGeneral outpatient settingProgenitor cell infusionTreatment-related mortalityMultiple myeloma patientsUse of ceftriaxoneApparent beneficial effectTransplant episodesMost patientsCell infusionFebrile patientsMedian timeMyeloma patientsRandomized trialsDecreased riskOutpatient therapyAmbulatory therapyOutpatient treatmentNeutropeniaCare providers